3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
9
Tumor-Agnostic
2
Thoracic
2
Gynecologic
2
Genitourinary
2
Head & Neck
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
575
Carboplatin
521
Cisplatin
351
Bevacizumab
252
pembrolizumab
228
Gemcitabine
157
Topotecan
128
Cyclophosphamide
128
liposomal doxorubicin
127
olaparib
120
Taxes
113
Radiotherapy
110
Docetaxel
94
Brachytherapy
89
Doxorubicin
84
Drug Therapy
81
niraparib
75
Nivolumab
71
Magnetic Resonance Spectroscopy
71
Specimen Handling
65
fludarabine
57
Biopsy
55
Hyperthermic Intraperitoneal Chemotherapy
53
Filgrastim
52
Letrozole
50
Oxaliplatin
48
durvalumab
47
Immunoglobulin G
47
atezolizumab
46
Platinum
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
bemarituzumab
×
Gynecologic
×
Clear all
NCT07146919
2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2
Withdrawn
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled